Scopolamine nasal spray in motion sickness: a randomised, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo
The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Abstract
Scopolamine has been used successfully for treatment of motion sickness for almost a century and the nasal administration was first studied 50 years ago. However, there never appeared a nasal dosage form. Finally, after finding a stable and suitable formulation for scopolamine, a study to investigate efficacy, safety, and tolerability was conducted, with a randomised, double-blind, double-dummy, crossover, Latin square design including placebo control and a placebo/placebo control for internal validity at the German Air Force Institute of Aviation Medicine. To assess the efficacy of a new, stable and well-tolerated formulation of scopolamine nasal spray the reproducible induction of whole body vibrations by a rotating chair was chosen and a validated seasickness score (SKS). The reduction of SKS showed that scopolamine nasal spray at a concentration of 0.2% was statistically superior to both placebo and dimenhydrinate (P=0.003 and 0.004, respectively). There were no signs for a nasal or epipharyngeal irritation of the mucous membrane. Scopolamine nasal spray was found to be an effective and safe treatment in motion sickness, with a fast onset of action within 30 min after administration.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Noninvasive IN formulation of scopolamine has higher peak plasma concentration and shorter peak time than oral agents [76,77].”
From Motion Sickness: Current Knowledge and Recent Advance. (2016) · cites this paper as [76]
Citations
Cites
Clinical Trials: A Practical Approach.
Hill, I. D., & Pocock, S. J. (1984) · Biometrics · doi:10.2307/2531186 · Cited by 2,930
Clinical trials: A practical approach
Daly, M. J. (1984) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(84)90515-7 · Cited by 1,053
Biomedical Results from Skylab. NASA SP-377
Johnston, R. S., & Dietlein, L. F. (1977) · NASA Technical Reports Server (NASA) · Cited by 768
(1968) · PubMed · Cited by 428
Money, K. E. (1970) · Physiological Reviews · doi:10.1152/physrev.1970.50.1.1 · Cited by 392
Spilker, B. (1991) · Cited by 330
Clinical Trials. A Practical Approach.
Seldrup, J., & Pocock, S. J. (1985) · The Statistician · doi:10.2307/2987660 · Cited by 227
Motion sickness in public road transport: passenger behaviour and susceptibility
TURNER, M. (1999) · Ergonomics · doi:10.1080/001401399185586 · Cited by 175
A theory of motion sickness based on pharmacological reactions
Wood, C. D., & Graybiel, A. (1970) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1970115621 · Cited by 90
Effects of gender of subjects and experimenter on susceptibility to motion sickness.
Jokerst, M. D., Gatto, M. R. A., Fazio, R. L., Pj, G., Stern, R. M., & Kl, K. (1999) · PubMed · Cited by 50
Cited by
Klinkenberg, I., & Blokland, A. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.04.001 · Cited by 696
Motion sickness susceptibility
Golding, J. F. (2006) · Autonomic Neuroscience · doi:10.1016/j.autneu.2006.07.019 · Cited by 399
Motion sickness: more than nausea and vomiting
Lackner, J. R. (2014) · Experimental Brain Research · doi:10.1007/s00221-014-4008-8 · Cited by 314
“Drugs such as promethazine and scopolamine provide protective benefit (Bar et al. 2009; Davis et al. 1993; G raybiel and Lackner 1987; Gordon et al. 2001; Klocker et al. 2001; Nachum et al. 2001, 2006; Simmons et al. 2010).”
BackgroundPharmacokinetics and Pharmacodynamics in Clinical Use of Scopolamine
Renner, U. D., Oertel, R., & Kirch, W. (2005) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000168293.48226.57 · Cited by 314
Motion Sickness: Current Knowledge and Recent Advance.
Zhang, L., Wang, J., Qi, R., Pan, L., Li, M., & Cai, Y. (2016) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12468 · Cited by 216
Metadata
- Authors
- Klöcker, N., Hanschke, W., Toussaint, S., & Verse, T.
- Affiliations
- Klinikum Frankfurt Höchst (DE)
- Universität Ulm (DE)
- Corresponding author
- Klöcker, Norbert
- Venue
- European Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 2001-05
- Volume
- 13
- Issue
- 2
- Pages
- 227-232
- ISSN
- 0928-0987 (ISSN-L)
- OpenAlex
- W2047033263
- Cited by
- 33
- References
- 24
- Citations by year
- 2024: 1 · 2023: 1 · 2022: 3 · 2020: 1 · 2019: 1 · 2018: 2 · 2017: 1 · 2015: 1 · 2014: 4 · 2013: 1 · 2012: 2
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- European Journal of Pharmaceutical Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Nausea and vomiting management
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Neuroscience › Neurology › Vestibular and auditory disorders
- Keywords
- scopolamine, nasal spray, motion sickness, seasickness, dimenhydrinate, antiemetic efficacy, drug stability, tolerability, onset of action, whole-body vibration
- MeSH terms
- Administration, Inhalation, Adolescent, Adult, Aged, Antiemetics, Dimenhydrinate, Female, Humans, Male, Middle Aged, Motion Sickness, Scopolamine, Treatment Outcome, Cross-Over Studies, Muscarinic Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Scopolamine nasal spray in motion sickness: a randomised, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo. https://app.cochat.ai/papers/10.1016/s0928-0987(01)00107-5
- The paper
- Klöcker, N., Hanschke, W., Toussaint, S., & Verse, T. (2001). Scopolamine nasal spray in motion sickness: a randomised, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo. European Journal of Pharmaceutical Sciences. https://doi.org/10.1016/s0928-0987(01)00107-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.